Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver

References

• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi:10.1038/nature05945
   PubMed Web of Science ®Google Scholar
• Rikova R, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:190–203. doi:10.1016/j.cell.2007.11.025
   Web of Science ®Google Scholar
• Ou SI, Lee ATM, Nagasaka M. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Crit Rev Oncol Hematol. 2023;187:104019. doi:10.1016/j.critrevonc.2023.104019
   PubMed Web of Science ®Google Scholar
• Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nat Cancer. 2023;4(3):330–343. doi:10.1038/s43018-023-00515-0
   PubMedGoogle Scholar
• Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903–21917. doi:10.18632/oncotarget.15746
   PubMedGoogle Scholar
• Pacheco JM, Gao D, Smith D, et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol. 2019;14(4):691–700. doi:10.1016/j.jtho.2018.12.014
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomized, open-label CROWN study. Lancet Respir Med. 2023;11(4):354–366. doi:10.1016/S2213-2600(22)00437-4
   PubMed Web of Science ®Google Scholar
• Ou SI, Nagasaka M, Brazel D, et al. Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? Transl Oncol. 2021;14(11):10. doi:10.1016/j.tranon.2021.101191
   Web of Science ®Google Scholar
• Lin JJ, Johnson M, Felip E, et al. Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors. Presented at the 35th AACR-NCI-EORTC symposium on October 13, 2023. Cancer Res. 2023;2023:1.
   Google Scholar
• Zhang SS, Nagasaka M, Zhu VW, et al. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer. 2021;158:126–136. doi:10.1016/j.lungcan.2021.06.012
   PubMed Web of Science ®Google Scholar
• Ou SH, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 2012;17(11):1351–1375. doi:10.1634/theoncologist.2012-0311
   PubMed Web of Science ®Google Scholar
• McLeer-Florin A, Duruisseaux M, Pinsolle J, et al. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer. 2018;116:15–24. doi:10.1016/j.lungcan.2017.12.004
   PubMed Web of Science ®Google Scholar
• Thorne-Nuzzo T, Willimas C, Catallini C, et al. A sensitive ALK immunohistochemistry companion diagnostic test identifies patients eligible for treatment with crizotinib. J Thorac Oncol. 2017;12(5):804–813. doi:10.1016/j.jtho.2017.01.020
   PubMed Web of Science ®Google Scholar
• Mok T, Peters S, Camidge DR, et al. Outcomes according to ALK status determined by central immunohistochemistry or fluorescence in situ hybridization in patients with ALK-Positive NSCLC enrolled in the phase 3 ALEX study. J Thorac Oncol. 2021;16(2):259–268. doi:10.1016/j.jtho.2020.10.007
   PubMed Web of Science ®Google Scholar
• Ou SI, Nagasaka M, Nagasaka M. A catalog of 5’ fusion partners in ALK-positive NSCLC circa 2020. JTO Clin Res Rep. 2020;1(1):100015. doi:10.1016/j.jtocrr.2020.100015
   PubMedGoogle Scholar
• Heuckmann JM, Balke-Want H, Malchers F, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012;18(17):4682–4690. doi:10.1158/1078-0432.CCR-11-3260
   PubMed Web of Science ®Google Scholar
• Horn L, Whisenant JG, Wakelee H, et al. Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. J Thorac Oncol. 2019;14(11):1901–1911. doi:10.1016/j.jtho.2019.08.003
   PubMed Web of Science ®Google Scholar
• Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14(7):1233–1243. doi:10.1016/j.jtho.2019.03.007
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L Trial. J Thorac Oncol. 2021;16(12):2091–2108. doi:10.1016/j.jtho.2021.07.035
   PubMed Web of Science ®Google Scholar
• Bearz A, Martini JF, Jassem J, et al. Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4:ALK variant type and ALK mutations. J Thorac Oncol. 2023;18:1581–1593. doi:10.1016/j.jtho.2023.07.023
   PubMed Web of Science ®Google Scholar
• Yang JC, Liu G, Lu S, et al. Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial. J Thorac Oncol. 2023;S1556–0864(23):730.
   Google Scholar
• Song Z, Lian S, Mak S, et al. Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-Rearranged NSCLC. J Thorac Oncol. 2022;17(2):264–276. doi:10.1016/j.jtho.2021.09.016
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Ou SI. Targeting alternative splicing as adjunctive treatment in EML4-ALK v3a/b+ NSCLC: knowing our Socratic paradox and learning from spinal muscular atrophy. J Thorac Oncol. 2022;17(2):182–185. doi:10.1016/j.jtho.2021.11.010
   PubMed Web of Science ®Google Scholar
• Zhu VW, Nagasaka M, Madison R, et al. A novel sequentially evolved EML4-ALK Variant 3 G1202R/S1206Y double mutation in cis confers resistance to lorlatinib: a brief report and literature review. JTO Clin Res Rep. 2020;2(1):100116. doi:10.1016/j.jtocrr.2020.100116
   PubMedGoogle Scholar
• Dziadziuszko R, Peters S, Mok T, et al. Circulating Cell-free DNA as a prognostic biomarker in patients with advanced ALK+ non-small cell lung cancer in the global phase III ALEX trial. Clin Cancer Res. 2022;28(9):1800–1808. doi:10.1158/1078-0432.CCR-21-2840
   PubMed Web of Science ®Google Scholar
• Okada K, Araki M, Sakashita T, et al. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBio Med. 2019;41:105–119. doi:10.1016/j.ebiom.2019.01.019
   PubMed Web of Science ®Google Scholar
• Bashari A, Siegfried Z, Karni R. Targeting splicing factors for cancer therapy. RNA. 2023;29(4):506–515. doi:10.1261/rna.079585.123
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Yoda S, Lennerz JK, et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin Cancer Res. 2020;26(11):2535–2545. doi:10.1158/1078-0432.CCR-19-3906
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Kiedrowski LA, Heist RS, et al. Efficacy and Tolerability of ALK/MET combinations in patients with ALK-rearranged lung cancer with acquired MET amplification: a retrospective analysis. JTO Clin Res Rep. 2023;4(8):100534. doi:10.1016/j.jtocrr.2023.100534
   PubMedGoogle Scholar
• Parikh K, Dimou A, Leventakos K, et al. Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC. J Clin Oncol. 2023;41(16_suppl):9029. doi:10.1200/JCO.2023.41.16_suppl.9029
   Web of Science ®Google Scholar
• Soo RA, Martini JF, van der Wekken AJ, et al. Early circulating tumor DNA dynamics and efficacy of lorlatinib in patients with treatment-naive, advanced, ALK-positive NSCLC. J Thorac Oncol. 2023;18(11):1568–1580. doi:10.1016/j.jtho.2023.05.021
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Bauer TM, Felip E, et al. Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment naive patients with ALK+ advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2022;40(16_suppl):9069. doi:10.1200/JCO.2022.40.16_suppl.9069
   Web of Science ®Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global Phase 2 study. Lancet Oncol. 2018;19(12):1654–1667. doi:10.1016/S1470-2045(18)30649-1
   PubMed Web of Science ®Google Scholar
• Lee JB, SI O. Plasma genotyping from the CROWN, ALTA-1L, and ALEX trials: can we speak with one voice on what to test, how to test, when to test, and for what purpose? J Thorac Oncol. 2023;18(11):1434–1442. doi:10.1016/j.jtho.2023.09.003
   PubMed Web of Science ®Google Scholar
• Drilon A, Lin JJ, Filleron T, et al. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol. 2018;13(10):1595–1601. doi:10.1016/j.jtho.2018.07.004
   PubMed Web of Science ®Google Scholar
• Ou SH, Soo RA, Kubo A, et al. Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally? Front Oncol. 2014;4:58. doi:10.3389/fonc.2014.00058
   PubMedGoogle Scholar